4.8 Review

Bridging Bio-Nano Science and Cancer Nanomedicine

Journal

ACS NANO
Volume 11, Issue 10, Pages 9594-9613

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.7b04855

Keywords

nanomaterials; nanoparticles; nanoengineering; antibodies; comparative oncology; metastasis; heterogeneity; tumor targeting

Funding

  1. Australian Research Council (ARC) [FL120100030]
  2. ARC Centre of Excellence in Convergent Bio Nano Science and Technology [CE140100036]
  3. National Health and Medical Research Council (NHMRC) [1084178]
  4. Victorian Government

Ask authors/readers for more resources

The interface of bio-nano science and cancer medicine is an area experiencing much progress but also beset with controversy. Core concepts of the field-e.g., the enhanced permeability and retention (EPR) effect, tumor targeting and accumulation, and even the purpose of nano in cancer medicine-are hotly debated. In parallel, considerable advances in neighboring fields are occurring rapidly, including the recent progress of immuno-oncology and the fundamental impact it is having on our understanding and the clinical treatment of the group of diseases collectively known as cancer. Herein, we (i) revisit how cancer is commonly treated in the clinic and how this relates to nanomedicine; (ii) examine the ongoing debate on the relevance of the EPR effect and tumor targeting; (iii) highlight ways to improve the next-generation of nanomedicines; and (iv) discuss the emerging concept of working with (and not against) biology. While discussing these controversies, challenges, emerging concepts, and opportunities, we explore new directions for the field of cancer nanomedicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available